Hello,
Wondering if anyone does IV lovenox at their institution and have information you're willing to share on what concentrations you prepare?
We're a children's hospital and we prepare 20 mG/mL concentration for all IV doses, and for SC doses LESS than 10 mg. We have request from hematology for lower concentrations. While the justification is sound we're struggling with data and even standards of practice in other places.

Thanks.
DiAnthia

The 2016 NIOSH document on hazardous drugs lists Megace in Group 1. They further indicated that PPE is required for administration of agents in Group 1. If I am reading this correctly, oral liquid formulations require basically the same PPE as that required for the administration of IV Chemotherapy.

How are you translating this into practice? I would like to get rid of Megace completely, but my docs are not on board.

Can anyone describe their process for the removal of medications that have been discontinued from a patient specific drawer? For example, we have had issues with vancomycin doses being changed (based on trough) and the old dose remaining in the patient's drawer.

Has anyone successfully instituted a system that informs the patient and/or family oft the medications they are receiving in the hospital on a daily basis?

Thanks,

Randi

How has your institution manage the dextrose 50% 50ml syringe shortage? We are looking into the use of Dextrose 10% IV piggy as an alternative. I found 2 studies but are mostly for emergency medicine.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1726850/pdf/v022p00512.pdf

https://www.ncbi.nlm.nih.gov/pubmed/24735872

I would greatly appreciate some insight.

Greetings,

Does anybody have a system-level policy/process regarding management of recalls for pharmaceuticals, medical equipment/devices, etc they could share? I’m specifically interested in any policies/mechanisms that include requirements for individual facilities to report back to system leadership about recall impact and actions taken in response to a recall (e.g., quantity on hand, quantity unaccounted for, removal of product from stock completed, # of patients affected, level of patient harm, was patient notification necessary, patient notification completed).

Hello,

I was hoping someone could provide information pertaining to the following questions.

1. Do you have any non-profiled Automatic Dispensing Machines (ADMs) in your institution?

If the answer is no, the survey ends here.

2. Do you audit medications pulled from ADMs against orders in non-profiled areas?

If the answer is no, the survey ends here.

Dear All:
I would like to enquire your process to identify and prevent patient allergies to medication excipients.
We had one patient who has a documented allergy to peanut and sesame oil. She was prescribed a medication suppository that contains a peanut oil.
This was not discovered by the patient's physician nor pharmacist, but it was discovered by the patient her self while reading about the medication in our patient education website.

Dear all,

Sharing with you an article about a narcotics diversion which resulted in outbreak of serratia marcescens.

http://www.infectioncontroltoday.com/news/2017/07/narcotics-diversion-re...

Rabih

For those of you using CPOT assessment in your ICUs, could you please share your protocol or policy? Specifically the guidance to nurses on titrating analgesic drips to reach appropriate doses (i.e. are you doing an “analgesic holiday”, how often, when to do the CPOT assessment after rate reduction, etc.). Any guidance or information would be greatly appreciated. Feel free to email me directly if preferred. Allyson.Fonte@msmc.com.

Thank you